drugset / Trial / NCT00565760
Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this trial.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Q8003 | Unknown | — | — |
Indications
No indication recorded.